ANALYST-UPGRADE filed
RBC Capital double-upgraded Pfizer from Underperform to Sector Perform, maintaining a $25 price target, which sits roughly 3% below the current price of $25.70. The upgrade reflects a less bearish view, though the unchanged target indicates limited near-term upside conviction. Consensus is deeply mixed at 42% Buy, 50% Hold, and 8% Sell across 36 analysts, with a mean target of $29.19 offering 13.6% implied upside. The median target is $28, while the low is $24, placing RBC's target at the bottom quartile. RBC's historical accuracy is 55% on over 4,100 calls with a 2.7% average return, above average among covering firms but not top tier. Analyst activity over the past 30 days shows only this upgrade and no downgrades, while EPS revisions are roughly balanced (30-day: 7 up/7 down for the next quarter, 12 up/7 down for the fiscal year). No insider trades were reported, and short interest is elevated at a 55.4% ratio. The double-upgrade from a previously bearish firm is a modest positive signal, but the unchanged target and mixed cross-platform data temper conviction. For active traders, the call is a tactical neutral-to-slightly-positive signal rather than a strong directional catalyst.